Advancing mRNA medicine through safer and more effective LNP delivery
‘Introducing ANNA: Turning Data into Better LNPs’
Lipid nanoparticles (LNPs) are a proven non-viral delivery mechanism for mRNA-based therapies, which continue to reshape modern medicine.
Key challenges in delivery remain before mRNA-based medicine can be unlocked to expand its reach.
At Axelyf, we are pairing our extensive expertise with AI-powered LNP design to accelerate mRNA therapy by designing more effective, precisely targeted, and more potent RNA delivery systems.
A team of experts, driven by passion and precision
Founded in Hafnarfjörður, Iceland, the Axelyf team leverages decades of expertise in pharmaceutical R&D and its global network of partners and collaborators to specialize in optimizing delivery systems for promising small molecule drugs derived from natural sources.